MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Opnurasib

CAS No. : 2653994-08-0

MCE 站：Opnurasib

产品活性：Opnurasib (JDQ-443) (NVP-JDQ443) 是一种口服有效和选择性的共价 KRAS G12C 抑制剂。Opnurasib 具有抗肿瘤活性。

研究领域：GPCR/G Protein  |  Cell Cycle/DNA Damage

作用靶点：Ras  |  PERK

In Vitro: Opnurasib (NVP-JDQ443) traps the GDP-bound inactive conformation of KRAS.
?Opnurasib promotes dose-dependent reductions of phosphorylated ERK (pERK) levels ａnd the proliferation of the KRASG12C-mutated cell lines NCI-H358 ａnd NCI-H2122, with IC₅₀ values of 0.018 ａnd 0.063 μM, respectively.
?Opnurasib covalently ａnd selectively binds ａnd inhibits GDP-bound KRASG12C with low reversible binding affinity to the RAS switch II pocket, ａnd also inhibits proliferation of KRASG12C-mutated ａnd KRAS G12C/H95, G12C/R68S, ａnd G12C/Y96 double-mutant cell lines.

In Vivo: Opnurasib (10-100 mg/kg, Orally, daily for 14 days) shows antitumor activity in KRAS G12C-mutated CDX models.
?Opnurasib (Orally, 100 mg/kg, daily (JDQ443) + 7.5 mg/kg, twice daily (TNO155), for 36 days) shows greater cell growth inhibition or cell killing compared with single-agent JDQ443 when combined with TNO155.
?Opnurasib generates categorical antitumor responses in PDX models of NSCLC ａnd colorectal tumors that are improved by combination treatment with other agents.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  GPCR/G Protein Compound Library  |  Kinase Inhibitor Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Ferroptosis Compound Library  |  Endoplasmic Reticulum Stress Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  LC-2  |  KRAS G12C inhibitor 54  |  MSU-42011  |  MRTX1133  |  AZA1  |  RBC10  |  CFL-137  |  Deltarasin hydrochloride  |  BDP9066  |  CCG-100602  |  KRAS inhibitor-4  |  KRas G12R inhibitor 1  |  MRTX0902  |  KRAS G12C inhibitor 25  |  PAT-IN-2  |  Antitumor agent-60  |  KRAS G12C inhibitor 30  |  KRas G12C inhibitor 1  |  Spiclomazine hydrochloride  |  GGTI-286 hydrochloride  |  6H05  |  AZD4625  |  SOS1-IN-6  |  Antineoplaston A10  |  K-Ras-IN-1  |  BI-0474  |  Diazepinomicin  |  MK-28

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。